Skip to main content

Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy

Objective

Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.

Call for proposal

H2020-JTI-IMI2-2019-18-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Address
Josef-schneider-strasse 2
97080 Wurzburg
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 594 995

Participants (26)

UNIVERSITA VITA-SALUTE SAN RAFFAELE
Italy
EU contribution
€ 629 550
Address
Via Olgettina 58
20132 Milano
Activity type
Higher or Secondary Education Establishments
UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 471 500
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 551 250
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
INSTITUT NATIONAL DU CANCER GIP
France
EU contribution
€ 551 260
Address
Avenue Andre Morizet 52
92513 Boulogne Billancourt
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 454 000
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany
EU contribution
€ 479 000
Address
Paul-ehrlich-strasse 51-59
63225 Langen
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
OSPEDALE PEDIATRICO BAMBINO GESU
Italy
EU contribution
€ 560 600
Address
Piazza Sant Onofrio 4
00165 Roma
Activity type
Other
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 571 911,25
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Spain
EU contribution
€ 510 688,75
Address
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Activity type
Other
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 539 750
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 562 750
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
T-CURX GMBH
Germany
EU contribution
€ 253 750
Address
Friedrich-bergius-ring 15
97076 Wurzburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN CANCER PATIENT COALITION
Belgium
EU contribution
€ 240 000
Address
Rue Montoyer 40
1000 Bruxelles
Activity type
Other
BIOSCI CONSULTING BVBA
Belgium
EU contribution
€ 476 000
Address
Weg Naar Geneuth 95
3631 Maasmechelen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 271 370
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
ERASMUS UNIVERSITEIT ROTTERDAM
Netherlands
EU contribution
€ 148 500
Address
Burgemeester Oudlaan 50
3062 PA Rotterdam
Activity type
Higher or Secondary Education Establishments
MILTENYI BIOTEC BV & CO KG
Germany
EU contribution
€ 277 500
Address
Friedrich Ebert Strasse 68
51429 Bergisch Gladbach
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU FUNDACION
Spain
EU contribution
€ 271 310
Address
C Sant Quinti 77-79
08041 Barcelona
Activity type
Research Organisations
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA
Luxembourg
EU contribution
€ 312 500
Address
9 Avenue Des Hauts-forneaux
4362 Esch-sur-alzette
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BAYER AKTIENGESELLSCHAFT
Germany
EU contribution
€ 0
Address
Kaiser-wilhelm-allee 1
51373 Leverkusen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JANSSEN PHARMACEUTICA NV
Belgium
EU contribution
€ 0
Address
Turnhoutseweg 30
2340 Beerse
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS
France
EU contribution
€ 0
Address
Rue Carnot 50
92284 Courbevoie
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TAKEDA PHARMACEUTICALS INTERNATIONAL AG
Switzerland
EU contribution
€ 0
Address
Thurgauerstrasse 130
8152 Glattpark
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN HEMATOLOGY ASSOCIATION
Netherlands
EU contribution
€ 0
Address
Koninginnegracht 12B/13
2514 AA Den Haag
Activity type
Other
ASTELLAS PHARMA EUROPE BV
Netherlands
EU contribution
€ 0
Address
Sylviusweg 84
2333 BE Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CELGENE MANAGEMENT SARL
Switzerland
EU contribution
€ 0
Address
Route De Perreux 1
2017 Boudry
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)